Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C-raf kinase

Anti-Cancer Drug Design

Volumn 12, Issue 5, 1997, Pages 409-420

  Henry, Scott P ^a   Monteith, David ^a   Bennett, Frank ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; ISIS 12854; ISIS 13650; ISIS 3521; NUCLEASE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; RAF PROTEIN; UNCLASSIFIED DRUG;

ANEMIA; BLOOD CHEMISTRY; BLOOD CLOTTING DISORDER; CANCER; COMPLEMENT ACTIVATION; DNA HYBRIDIZATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; ENZYME DEFECT; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

ANIMALS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; THIONUCLEOTIDES;

EID: 0030797705     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. AGRAWAL, S., RUSTAGI, P.K. & SHAW, D.R. (1995a). Novel enzymatic and immunological responses to oligonucleotides. Toxicology Letters, 82-3, 431.
2. AGRAWAL, S , TEMSAMANI, J., GALBRAITH, W. & TANG, J (1995b). Pharmacokinetics of antisense oligonucleotides. Drug Disposition, 28, 7.
3. ALAHARI, S.K., DEAN, N.M., FISHER, M H, DELONG, R, MANOHARAN, M., TIVEL, K.L. & JULIANO, R.L. (1996). Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Molecular Pharmacology, 50, 808.
4. ALTMANN, K.-H., DEAN, N.M., FABBRO, D , FREIER, S.M , GEIGER, T., HANER, R., HUSKEN, D , MARTIN, P., MONIA, B.P , MULLER, M , NATT, F , NICKLIN, P , PHILLIPS, J., PIELES, U., SASMOR, H. & MOSER, H. E. (1996a). Second generation of antisense oligonucleotides: from nuclease resistance to biological efficant in animals. Chimia, 50, 168.
5. ALTMANN, K H., FABBRO, D., DEAN, N.M. GEIGER, T, MONIA, B.P., MUULER, M. & NICKLIN, P (1996b). Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal transduction inhibitors. Biochemical Society Transactions, 24, 630.
6. BRANDA, R.F., MOORE, A.L , MATHEWS, L., MCCORMACK, J.J. & ZON, G. (1993). Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochemical Pharmacology, 45, 2037.
7. BROWN, D.A , KANG, S.-H., GRYAZNOV, S M., DEDIONISIO, L., HEIDENREICH, O., SULLIVAN, S., XU, X. & NERENBERG, M.I. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides of specific protein binding. Journal of Biological Chemistry, 269, 26801.
8. CAMPBELL, J.M., BACON, T.A. & WICKSTROM, E. (1990). Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. Journal of Biochemical and Biophysical Methods, 20, 259.
9. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. Journal of Pharmacology and Experimental Therapeutics, 267, 1181.
10. CROOKE, S.T. (1995). The future of antisense technology. Pharmaceutical News, 2, 8.
11. CROOKE, S.T. & BENNETT, C.F. (1996). Progress in antisense oligonucleotide therapeutics. Annual Review of Pharmacology and Toxicology, 36, 107.
12. CROOKE, S.T., LEMONIDIS, K.M., NEILSON, L., GRIFFEY, R., LESNIK, E.A. & MONIA, B.P. (1995). Kinetic characteristics of E. coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochemical Journal, 312, 599.
13. CROOKE, S.T., GRAHAM, M J., ZUCKERMAN, J.E., BROOKS, D., CONKLIN, B.S., CUMMINS, L L., GREIG, M J , GUINOSSO, C.J., KORNBRUST, D., MANOHARAN, M., SASMOR, H. M., SCHLEICH, T., TIVEL, K.L. & GRIFFEY, R.H. (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. Journal of Pharmacology and Experimental Therapeutics, 277, 923.
14. CUMMINS, L.L., OWENS, S.R., RISEN, L.M , LESNIK, E.A., FREIER, S.M., MCGEE, D., GUINOSSO, C. J. & COOK, P.D. (1995). Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Research, 23, 2019.
15. DEAN, N.M., MCKAY, R., MIRAGLIA, L , HOWARD, R., COOPER, S., GIDDINGS, J., NICKLIN, P., MEISTER, L., ZIEL, R., GEIGER, T., MULLER, M. & FABBRO, D. (1996). Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Research, 56, 3499.
16. GEARY, R.S., LEEDS, J M., HENRY, S P, MONTEITH, D., TRUONG, L., FITCHETT, J., BURCKIN, T. & LEVIN, A.A. (1996). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Design, 12, 383.
17. GRIFFEY, R.H. LESNIK, E., FRIER, S., SANGHVI, Y.S., TENG, K., KAWASAKI, A , GUINOSO, C., WHEELER, P., MOHAN, V. & COOK, P.D (1994). New Twists on Nucleic Acids: Structural Properties of Modified Nucleosides Incorporated into Oligonucleotides. Sanghvi, Y.S. & Cook, P.D. (eds) , Vol. 580, p. 212. American Chemical Society, Washington, DC.
18. HENRY, S.P., LARKIN, R., NOVOTNY, WF. & KORNBRUST, D.J. (1994). Effects of ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Pharmaceutical Research, 11, S-353.
19. HENRY, S.P., BOLTE, H. AULETTA, C. & KORNBRUST, D.J. (1996a). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology, in press.
20. HENRY, S P., TAYLOR, J., MIDGLEY, L., LEVIN, A.A. & KORNBRUST, D.L. (1996b). Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide, following repeated intravenous administration, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Development, in press.
21. HENRY, S.P., GICLAS, P.C., LEEDS, J., PANGBURN, M., AULETTA, C., LEVIN, A.A. & KORNBRUST, D.J. (1997a). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. Journal of Pharmacology and Experimental Therapeutics, 281, 810.
22. HENRY. S.P , ORR, J.L , BRUNNER, R.H. & KORNBRUST, D J. (1997b). Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology, 116, 77.
23. HENRY, S.P. ZUCKERMAN, J.E., ROJKO, J., HALL, W.C., HARMAN, R.J., KITCHEN, D. & CROOKE, S.T. (1997c). Toxicologic properties of several novel oligonucleotide analogs in mice. Anti-Cancer Drug Design, 12, 1.
24. HOKE, G.D., DRAPER, K., FREIER, S.M., GONZALEZ, C., DRIVER, VB., ZOUNES, M.C. & ECKER, D.J (1991). Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Research, 19, 5743.
25. KRIEG, A.M., YI, A.-K., MATSON, S., WALDSCHMIDT, T.J., BISHOP, G.A., TEASDALE, R., KORETZKY, G.A. & KLINMAN, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374, 546.
26. KRIEG, A.M., MATSON, S. & FISHER, E. (1996). Oligonucleotide modification determine the magnitude of B-cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Development, 6, 133.
27. MCKAY R A., CUMMINS, L.L., GRAHAM, M.J., LESNIK, E.A., OWENS, S.R., WINNIMAN, M. & DEAN, N.M. (1996). Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2′-O-propyl modifications. Nucleic Acids Research, 24, 411-417.
28. METELEV, V., LISZIEWWICZ, J. & AGRAWAL, S. (1994). Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-methoxyoligoribonucleotides. Bioorganic and Medicinal Chemistry, 4, 2929.
29. MONIA, B.P., LESNIK, E.A., GONZALEZ, C., LIMA, W.F., MCGEE, D, GUINOSSO, C.J., KAWASAKI, A.M., COOK, P.D. & FREIER, S.M. (1993). Evaluation of 2′ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression. Journal of Biological Chemistry, 268, 14514.
30. MONIA, B , JOHNSTON J F., SASMOR, H. & CUMMINS, L.L. (1996a). Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. Journal of Biological Chemistry, 24, 14533.
31. MONIA, B.P , JOHNSTON, J.F., GEIGER, T., MULLER, M. AND FABBRO, D. (1996b). Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature and Medicine, 2, 668.
32. OBERBAUER, R., SCHREINER, G. F. & MEYER, T.W. (1995). Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney International, 48, 1226.
33. SARMIENTO, U.M., PEREZ, J.R., BECKER, JM & NARAYANAN, R (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Research and Development, 4, 99.
34. SRINIVASAN, S.K., TEWARY, H. K. & IVERSEN, P.L. (1995). Characterization of binding sites, extent of binding and drug interactions of oligonucleotides with albumin. Antisense Research and Development, 5, 131.
35. WALLACE, T L., BAZEMORE, S.A., KORNBRUST, D.J. & COSSUM, P.A. (1996). Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. 1. Journal of Pharmacology and Experimental Therapeutics, 278, 1306.
36. ZHANG, R , LU, Z , ZHANG, X., ZHAO, H , DIASIO, R.B., LIU, T., JIANG, Z. & AGRAWAL, S. (1995a). In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clinical Chemistry, 41, 836.
37. ZHANG, R., LU, Z., ZHAO, H., ZHANG, X., DIASIO, R., HABUS, I JIANG, Z , IYER, R.P., YU, D. & AGRAWAL, S. (1995b). In vivo stability, disposition and metabolism of a 'hybrid' oligonucleotide phosphorothioate in rats. Biochemical Pharmacology, 50, 454.
38. ZHAO, Q., TEMSAMANI, J., IADAROLA, P.L., JIANG, Z. & AGRAWAL, S (1996). Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochemical Pharmacology, 51, 173.